Moonlight AI Raises $3.3M in Seed Funding

Why It Matters

By turning inexpensive slide imaging into actionable genomic data, Moonlight AI could dramatically cut costs and turnaround times in precision oncology, accelerating patient‑specific treatment decisions worldwide.

Key Takeaways

• Moonlight AI secured €2.8M (~$3.3M) seed funding.
• AI extracts genomic biomarkers from routine blood and cytology slides.
• Funding expands proprietary image‑genomics data library and team.
• Products target myelodysplastic syndrome, NSCLC, and CLL diagnostics.
• Transition to Swiss AG positions firm for international commercialization.

Pulse Analysis

Precision oncology increasingly depends on rapid, affordable access to genomic information, yet next‑generation sequencing remains expensive and slow. Moonlight AI’s computer‑vision platform sidesteps these bottlenecks by analyzing standard hematology and cytology slides, converting visual patterns into actionable genetic insights. This approach leverages existing laboratory hardware, reducing capital outlay and enabling labs to deliver faster, molecular‑level diagnoses without the need for dedicated sequencing instruments.

The €2.8 million seed round, co‑led by investors from Singapore, Switzerland and Tunisia, underscores growing confidence in AI‑driven diagnostics. Investors cite the startup’s proprietary dataset that links whole‑slide imaging with high‑quality genomic annotations—a rarity that fuels model robustness across diverse patient populations. By expanding this data consortium, Moonlight AI aims to improve algorithmic accuracy, meet regulatory standards, and attract additional clinical partners seeking to modernise their workflow.

Looking ahead, Moonlight AI’s focus on myelodysplastic syndrome, non‑small cell lung cancer and chronic lymphocytic leukaemia positions it within high‑impact oncology niches where early, precise treatment decisions are critical. The transition to a Swiss Aktiengesellschaft provides a solid corporate framework for international expansion and potential public listing. If the company secures regulatory clearance, its technology could reshape diagnostic pathways, lower costs for health systems, and accelerate the delivery of personalized cancer therapies worldwide.

Deal Summary

Swiss startup Moonlight AI announced the closing of a €2.8 million ($3.3 million) Seed funding round, co‑led by Lotus One Investment, VP Venture Partners and MEDIN Fund, with participation from N&V Capital and QAI Ventures. The capital will be used to expand its AI‑driven diagnostic platform that converts routine blood and cytology imaging into genomic insights, grow its data library and accelerate commercialization.